The majority of patients were younger than 60 years of age at randomisation (58% in the 6-year group versus 59% in the 3-year group), had node-positive disease (68% versus 66%), and were diagnosed with tumours expressing both oestrogen and progesterone receptors (76% in both treatment groups). The gene discussed is PGR; the disease is neoplasm.